Tracer library / [161Tb]Tb-PSMA-I&T
[161Tb]Tb-PSMA-I&T
Also written as PSMA I&T; PSMA-I&T; [Tb-161]Tb-PSMA-I&T
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting radioligand (small-molecule PSMA inhibitor)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 37442604
- Clinical application
- Metastatic castration-resistant prostate cancer (mCRPC) PMID 38991752
- Theranostic pair
- [68Ga]Ga-PSMA-I&T
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| miniAllinOne Trasis | — | — | — | ~99% | PSMA-1 | 42334711 2026 EJNMMI Radiopharm Chem via a Trasis MiniAiO synthesizer |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
Need this precursor?We can point you to suppliers for [161Tb]Tb-PSMA-I&T, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 42334711: '[161Tb]Tb-PSMA-1'. Stage set/updated at stage 39 from PMID 38991752: 'Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T.'.